Genton P, Gélisse P
Centre Saint-Paul, 300, boulevard Saint-Marguerite, 13009 Marseille, France.
Epileptic Disord. 2000 Dec;2(4):209-12.
Treatment of severe, incapacitating action myoclonus is difficult. Piracetam has been shown to be a very potent antimyoclonic agent, but only at very high, impractical doses, ranging from 24 to 40 g/d. Levetiracetam (LEV), a new antiepileptic drug, is a structurally related compound that has a distinct pharmacological profile and appears to be efficient at much lower doses. We gave LEV, 4,000 mg/d, without titration, to three volunteers with post-anoxic myoclonus (PAM) (one case) and Unverricht-Lundborg disease (two cases), over 2, 2 and 10 weeks, respectively. LEV produced a clear abatement of myoclonus, which is demonstrated on video for the patient with post-anoxic myoclonus, without any unwanted side-effects. These preliminary findings suggest that LEV may have interesting antimyoclonic properties that deserve further investigation.
重度失能性动作性肌阵挛的治疗颇具难度。已证实吡拉西坦是一种非常有效的抗肌阵挛药物，但仅在24至40克/天的非常高且不切实际的剂量下才有效。左乙拉西坦（LEV）是一种新型抗癫痫药物，是一种结构相关化合物，具有独特的药理学特性，且在低得多的剂量下似乎也有效。我们分别在2周、2周和10周内，给予三名患有缺氧后肌阵挛（PAM）（1例）和翁韦里希特 - 伦德伯格病（2例）的志愿者每天4000毫克左乙拉西坦，且未进行滴定。左乙拉西坦使肌阵挛明显减轻，缺氧后肌阵挛患者的情况在视频中得到了展示，且未出现任何不良副作用。这些初步发现表明，左乙拉西坦可能具有值得进一步研究的有趣抗肌阵挛特性。
